These immature cells were impaired at turning into mature, specialized cells called cortical neurons--the most affected cell type in frontotemporal dementia
A presenilin 1 mutation associated with familial frontotemporal dementia
inhibits gamma-secretase cleavage of APP and notch.
The company's tau aggregation inhibitor, LMTX(TM), is currently in global Phase 3 clinical trials for Alzheimer's and Frontotemporal Dementia
Researchers at the Gladstone Institutes and University of California, San Francisco have shown that a loss of cells in the retina is one of the earliest signs of frontotemporal dementia
(FTD) in people with a genetic risk for the disorder -- even before any changes appear in their behavior.
Coverage also includes diagnostic issues, the neuropsychological profile of the disease, frontotemporal dementia
, animal models, inflammation, treatment strategies, and the future of the disease.
Twenty-seven European and North American academics and practitioners contribute 19 chapters offering mental health professionals as well as general practitioners and students an up-to-date discussion of new evidences from basic and clinical sciences concerning four major dementing illnesses likely to be encountered in a daily practice: Alzheimer's disease, vascular dementia, Lewy body disease, and frontotemporal dementia
National Institute on Aging (NIA) News Release "Scientists Discover New Frontotemporal Dementia
Gene", Monday, July 17, 2006
The differential diagnosis includes hydrocephalus, other dementias (Alzheimer's disease, frontotemporal dementia
Here we review the path from gene discovery to development of a clinical genetic test using frontotemporal dementia
with parkinsonism linked to chromosome 17 (FTDP-17)  as an example of a complex, rare genetic condition.
Three new studies show that mutations in the gene that encodes the tau protein underlie some forms of frontotemporal dementia
Early Symptoms of Frontotemporal Dementia
Provide Insights into Orbitofrontal Cortex Function and Social Behavior
Initial focus to identify protein targets and design molecules that inhibit their activity for diseases such as Huntington's disease, amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy (PSP), and frontotemporal dementia